BAYER, ASPIRIN REGIMEN OTC
Generic Name and Formulations:
Aspirin 81mg tabs, 325mg caplets; e-c.
Bayer Corp, Consumer Care Div.
Indications for BAYER, ASPIRIN REGIMEN:
To reduce combined risk of death and nonfatal stroke after ischemic stroke or TIA. To reduce risk of vascular mortality in suspected acute MI. To reduce combined risk of death and nonfatal MI after MI or unstable angina pectoris. To reduce combined risk of MI and sudden death in chronic stable angina. Revascularization procedures.
Ischemic stroke and TIA: 50–325mg once daily. Suspected acute MI: 160–162.5mg once daily (start as soon as MI suspected) then for at least 30 days post-MI. Prevention of recurrent MI, unstable angina pectoris, chronic stable angina: 75–325mg once daily. Coronary artery bypass graft: 325mg once daily (start 6hrs after procedure) for 1yr. Percutaneous transluminal coronary angioplasty: 325mg 2 hours before surgery, then 160–325mg once daily. Carotid endarterectomy: 80mg once daily to 650mg twice daily (start before surgery).
NSAID allergy. Viral infection in children and teenagers. 3rd trimester pregnancy.
History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy, nursing mothers: not recommended.
Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction.
GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism.
Aspirin Regimen 81mg—32, 120, 180; Aspirin Regimen 325mg—100; Children's—36; Bayer Tabs—12, 24, 50, 100, 200, 300, 365; Caplets—50, 100, 200; Gelcaps—40, 80
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States